Biomarker Selection for Maintenance Therapy in Advanced NSCLC - a podcast by American Society of Clinical Oncology (ASCO)

EGFR mutation is a predictive biomarker for maintenance erlotinib but its clinical application is limited. This podcast will explain why.

Further episodes of Journal of Clinical Oncology (JCO) Podcast

Further podcasts by American Society of Clinical Oncology (ASCO)

Website of American Society of Clinical Oncology (ASCO)